CIK 310158
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 66.81% | 10 |
| Health Care Providers & Services | 25.60% | 1 |
| Unclassified | 7.59% | 3 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | MRNA | Moderna, Inc. | Health Care | 33.56% |
| 2 | PSNL | Personalis, Inc. | Health Care | 25.60% |
| 3 | KYMR | Kymera Therapeutics, Inc. | Health Care | 18.40% |
| 4 | ENTRADA THERAPEUTICS INC | Unclassified | 6.28% | |
| 5 | EIKN | Eikon Therapeutics, Inc. | Health Care | 5.05% |
| 6 | AKTS | Aktis Oncology, Inc. | Health Care | 4.88% |
| 7 | ALEC | Alector, Inc. | Health Care | 2.18% |
| 8 | STRO | SUTRO BIOPHARMA, INC. | Health Care | 1.94% |
| 9 | EVAXION BIOTECH A/S | Unclassified | 1.29% | |
| 10 | VRDN | Viridian Therapeutics, Inc.\DE | Health Care | 0.52% |
11/14 names classified · sector 92.4% of weight · industry 92.4% · mkt cap 87.5%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 92.4% of the book is sector-classified (unclassified names shown, never dropped).
Only 0% of book weight classified — the grid is NOT representative of the whole book.
Classified: 0.0% of book weight (0/13 names) · unclassified 100.0%: MRNA, PSNL, KYMR, , EIKN, AKTS, ALEC, STRO, VRDN, XLO +3 more. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | MRNAMODERNA INC | 2,308,190 | $117M | 33.6% | HOLD |
| 2 | PSNLPERSONALIS INC | 14,044,943 | $89M | 25.6% | HOLD |
| 3 | KYMRKYMERA THERAPEUTICS INC | 772,165 | $64M | 18.4% | HOLD |
| 4 | ENTRADA THERAPEUTICS INC | 1,739,768 | $22M | 6.3% | HOLD |
| 5 | EIKNEIKON THERAPEUTICS INC | 1,666,666 | $18M | 5.0% | NEW |
| 6 | AKTSAKTIS ONCOLOGY INC | 952,844 | $17M | 4.9% | NEW |
| 7 | ALECALECTOR INC | 3,545,719 | $8M | 2.2% | HOLD |
| 8 | STROSUTRO BIOPHARMA INC | 272,351 | $7M | 1.9% | HOLD |
| 9 | EVAXION BIOTECH A/S | 1,214,126 | $5M | 1.3% | HOLD |
| 10 | VRDNVIRIDIAN THERAPEUTICS INC | 93,414 | $2M | 0.5% | HOLD |
| 11 | XLOXILIO THERAPEUTICS INC | 105,982 | $891,309 | 0.3% | NEW |
| 12 | CARMCARISMA THERAPEUTICS INC | 1,473,240 | $47,880 | 0.0% | HOLD |
| 13 | NEUPNEUPHORIA THERAPEUTICS INC | 10,027 | $40,810 | 0.0% | HOLD |
| 14 | HURATUHURA BIOSCIENCES INC | 19,445 | $34,807 | 0.0% | ADD 39% |
| Security | 2024-Q4 | 2025-Q1 | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 | Latest value |
|---|---|---|---|---|---|---|---|
| MRNAMODERNA INC | 2.3M | 2.3M | 2.3M | 2.3M | 2.3M | 2.3M | $117M |
| PSNLPERSONALIS INC | 14.0M | 14.0M | 14.0M | 14.0M | 14.0M | 14.0M | $89M |
| KYMRKYMERA THERAPEUTICS INC | 772K | 772K | 772K | 772K | 772K | 772K | $64M |
| ENTRADA THERAPEUTICS INC | 1.7M | 1.7M | 1.7M | 1.7M | 1.7M | 1.7M | $22M |
| EIKNEIKON THERAPEUTICS INC | — | — | — | — | — | 1.7M | $18M |
| AKTSAKTIS ONCOLOGY INC | — | — | — | — | — | 953K | $17M |
| ALECALECTOR INC | 3.5M | 3.5M | 3.5M | 3.5M | 3.5M | 3.5M | $8M |
| STROSUTRO BIOPHARMA INC | 2.7M | 2.7M | 2.7M | 2.7M | 272K | 272K | $7M |
| EVAXION BIOTECH A/S | 542K | 1.2M | 1.2M | 1.2M | 1.2M | 1.2M | $5M |
| VRDNVIRIDIAN THERAPEUTICS INC | 93K | 93K | 93K | 93K | 93K | 93K | $2M |
| XLOXILIO THERAPEUTICS INC | — | — | — | — | — | 106K | $891,309 |
| CARMCARISMA THERAPEUTICS INC | 1.5M | 1.5M | 1.5M | 1.5M | 1.5M | 1.5M | $47,880 |
| NEUPNEUPHORIA THERAPEUTICS INC | 10K | 10K | 10K | 10K | 10K | 10K | $40,810 |
| HURATUHURA BIOSCIENCES INC | — | — | 14K | 14K | 14K | 19K | $34,807 |
Shares reported each quarter by the largest current holdings. Green = added vs the prior filing of that name, red = trimmed, grey = roughly held; a dash is a quarter with no 13F on file (a gap is skipped, not read as an exit). 13F is filed up to 45 days after quarter-end. Up to 40 quarters (10 years) available — use the selector above.
Where this firm's principals came from and which firms its alumni went on to found.
